Studies have shown that serum RBP4 level is correlated with hepatocellular injury in patients with nonalcoholic fatty liver disease (NAFLD), and that it is also a new marker for virus-induced steatosis in patients infected with HCV having genotype 1 [22][23]. This evidence concerns the gene RBP4 and metabolic dysfunction-associated steatotic liver disease.